MedTrace Logo

Adjuvant Growth Therapy in in Vitro Fertilization

NCT01715324 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 288

Last updated 2022-01-11

No results posted yet for this study

Summary

In an In Vitro Fertilization (IVF) cycle super ovulating drugs (gonadotropins) are usually taken to stimulate the ovaries to produce more than one egg. In Vitro Fertilization protocols are constantly under review in order to improve the recruitment of the follicles, which contain the eggs, whilst minimizing the doses of gonadotrophins required, with the ultimate aim of increasing the live birth rate.

Conditions

Interventions

DRUG

Adjuvant Growth Hormon

The treatment group will receive 2.5 mg of Saizen daily via subcutaneous injections, from the beginning of the ovarian reserve stimulation until the day of the ovulation triggering

Sponsors & Collaborators

  • EMD Serono

    collaborator INDUSTRY

  • Clinique Ovo

    lead INDUSTRY

Principal Investigators

  • Jacques Kadoch, MD · Clinique Ovo

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
42 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-25
Primary Completion
2021-07-31
Completion
2021-08-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01715324 on ClinicalTrials.gov